Neuroendocrine Cancer

FDG PET for neuroendocrine cancer

PET that uses FDG (a type of tagged sugar) is not all that sensitive in neuroendocrine cancers(NET). This means that it may not pick up some neuroendocrine cancers. Specificity means that what it does pick up is really cancer and not some other false positive. However, other imaging modalities also had disadvantages as well as advantages.  One study revealed that for neuroendocrine tumors, PET that used 18F-FDOPA was more accurate (sensitivity,

Read more
Liver transplantation for neuroendocrine cancer

Liver transplantation can theoretically cure cancers which are slow growing and may be restricted to the liver at the time of transplantation. It can cure, for example, some hepatocellular carcinomas. Liver transplantation for the treatment of metastatic neuroendocrine tumors (NETs) has a several decade history and also results in an occasional cure. The reported experience with transplantation for NETs is limited to about 150 cases with widely varying

Read more
PET for neuroendocrine cancer

FDG PET is not all that sensitive in neuroendocrine cancers(NET). This may relate to how neuroendocrine cancer takes up FDG in comparison to other radio-labels used for PET scanning. One study revealed that for neuroendocrine tumors, 18F-FDOPA scanning was more sensitive and accurate (sensitivity, 100%; specificity, 91%) in the detection of skeletal lesions than octreotide scintigraphy or CT but was not sensitive (sensitivity, 20%; specificity, 94%)

Read more
TACE for Liver Metastases from Ovarian Cancer

Transcatheter arterial chemoembolization (TACE) of the liver is an alternative to conventional systemic or intra-arterial chemotherapy, and to various nonsurgical tumor-killing techniques. It is meant to treat resectable and non-resectable tumors. The rationale for TACE is that infusions of viscous material containing one or more chemo drugs may have synergy: chemotherapy killing cancer cells that are already weakened from a lack of oxygen in the

Read more